Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)

NCT02973113 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT02973113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2016
Completion date
July 11, 2020
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ebv related hodgkin's lymphoma, ebv related lymphoma, ebv related non-hodgkin's lymphoma, ebv-related ptld, hodgkin lymphoma, lymphoproliferative disorders, nonhodgkin lymphoma